Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

Six of nine patients at the highest 740 mg daily dose group experienced moderate ... while Viking's VK2735 – like Zepbound, a dual GLP-1 and GIP agonist – also achieved a 3.3% reduction ...

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...